"Taking the present situation in Denmark into account, what we are currently losing in our effort to prevent severe illness from Covid-19 cannot outweigh the risk of causing possible side effects in the form of severe blood clots in those we vaccinate," the Danish Health Authority's Deputy Director-General Helene Probst said in a statement on Monday. 

"In the midst of an epidemic, this has been a difficult decision to make, especially since we have also had to discontinue using the Covid-19 vaccine from AstraZeneca." 

The Authority's decision that "the benefits do not outweigh the risks" comes after the European Medicines Agency (EMA) concluded that a possible link existed between rare but severe cases of blood clots (vaccine-induced immune thrombotic thrombocytopenia or VITT) and the vaccine from Johnson & Johnson, reports Xinhua news agency. 

The decision will affect those in the 20 to 39 age group, who will now face a delay of up to four weeks in their vaccination, according to the statement. 

However, the Authority noted that the decision does not rule out that Johnson & Johnson vaccines may be used later. 

On April 14, Denmark decided to entirely cease administering the AstraZeneca Covid-19 vaccine. 

The jabs from Pfizer/BioNTech and Moderna are currently included in the country's official vaccination program. 

Nevertheless, Danish citizens still have the opportunity to choose both the dropped AstraZeneca and Johnson & Johnson Covid-19 vaccines voluntarily and for free. 

In a majority vote, the Danish Parliament has supported the decision. 

The optional vaccination scheme is expected to begin in May, the Danish news agency Ritzau reported on Monday. 

According to the Statens Serum Institut (SSI), Denmark on Monday registered 762 new cases with no new deaths in the past 24 hours. 

To date, the country has reported 253,673 cases and 2,490 deaths, while 1,367,495 Danes have received at least one shot of a Covid-19 vaccine, which corresponds to 23.4 per cent of the population.